Wockhardt (WOCKPHARMA) Share Price Fall Streak Extends to Second Straight Session
- September 15, 2026
- Posted by: Harsh Piplani
- Category: News
Wockhardt Share Price Fall Streak extended into the second straight session on 15 September 2026, with the stock closing at Rs 2,075 after a cumulative 6.53% decline from the streak base price of Rs 2,219.9 on 2026-09-11. Today’s move alone was a 4.87% fall, and the supplied data confirms the two-session pattern. However, the verified figures do not establish any company-specific cause for the continued decline.
The latest session opened at Rs 2,184.75 after the previous close of Rs 2,181.15, touched Rs 2,193.35 and Rs 2,068.4, and ended at Rs 2,075. Turnover stood at Rs 19.88 crore and market capitalisation was Rs 35,441.98 crore. For readers tracking Wockhardt Share Price Fall Streak on Univest, the main takeaway is that the stock finished lower again rather than reversing the earlier weakness.
Wockhardt (WOCKPHARMA) Share Price Fall Streak: Consecutive Decline Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,075 |
| Previous Close | Rs 2,181.15 |
| Today's Move | -Rs 106.15 (-4.87%) |
| Open | Rs 2,184.75 |
| High | Rs 2,193.35 |
| Low | Rs 2,068.4 |
| Turnover | Rs 19.88 crore |
| Market Capitalisation | Rs 35,441.98 crore |
Wockhardt Share Price Fall Streak remained the central market development in this session as the stock slipped Rs 106.15 from the prior close. The day’s range from Rs 2,193.35 to Rs 2,068.4 shows that weakness persisted through trading and the close stayed close to the low, which kept the decline intact into the finish. Wockhardt Share Price Today therefore reflects continued selling pressure rather than a brief intraday dip.
The two-session nature of the move is what makes Wockhardt Share Price Fall Streak more important than a single weak day. The stock has now posted back-to-back lower closes, and the cumulative drop of 6.53% from the 2026-09-11 base price of Rs 2,219.9 is the clearest verified measure of that pattern. Today’s fall contributed most of the damage, which is why the latest lower close matters in assessing the stock’s near-term tone.
What the Consecutive Declines Show
Two consecutive lower closes indicate that the weakness has carried beyond one trading session and has become a short-term price pattern. In Wockhardt’s case, the current streak now totals a 6.53% decline from the base level of Rs 2,219.9, with the latest close at Rs 2,075 confirming that the stock remained under pressure through the second straight session.
That matters because Wockhardt Share Price Fall Streak is no longer just about a one-day drop. The second straight session shows that the previous session’s weakness was not fully absorbed, and the latest close kept the stock below the prior day’s level. The supplied data does not confirm any company-specific trigger, so the focus stays on the verified streak itself: two lower closes, a 6.53% cumulative fall and a session that ended near its low.
Wockhardt (WOCKPHARMA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 35,441.98 crore |
| P/E Ratio | 86.66x |
| P/B Ratio | 7.04x |
| ROE | 4.29% |
| ROCE | 6.79% |
| EPS | Rs 25.17 |
| Book Value Per Share | Rs 309.81 |
| Dividend Yield | 0% |
Wockhardt Fundamental Analysis provides context for the decline, even though it does not assign a reason for the day’s move. The company trades at a P/E of 86.66 and a P/B of 7.04, while EPS is Rs 25.17 and book value per share is Rs 309.81. Dividend yield is 0%, so the supplied data does not show any dividend support in the current setup.
Profitability is modest in the same dataset. ROE is 4.29% and ROCE is 6.79%, which places the stock below the stronger return profile seen in several listed pharma names. That does not explain the latest fall on its own, but it does help explain why Wockhardt Share Price Fall Streak is drawing attention alongside Wockhardt Share Price News and broader Wockhardt Stock Analysis.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 86.66x |
| Benchmark Median P/E | 32.72x |
| Benchmark Average P/E | 49.15x |
| Benchmark P/E Range | 3.34x to 693.7x |
| Company P/B Ratio | 7.04x |
| Benchmark Median P/B | 3.05x |
| Benchmark Average P/B | 4.37x |
| Company ROE | 4.29% |
| Benchmark Median ROE | 11.69% |
| Benchmark Average ROE | 10.54% |
| Company ROCE | 6.79% |
| Benchmark Median ROCE | 13.24% |
| Benchmark Average ROCE | 13.09% |
| Company Market Capitalisation | Rs 35,441.98 crore |
| Benchmark Median Market Cap | Rs 704.59 crore |
| Benchmark Average Market Cap | Rs 13,873.11 crore |
The stock sits in Healthcare, within the Pharmaceuticals & Drugs industry, and the benchmark set includes 204 companies in the same industry. That gives a broad comparison base for valuation and profitability, which is useful when reviewing a decline story such as Wockhardt Share Price Fall Streak.
On the supplied figures, Wockhardt’s P/E of 86.66 is above the industry median of 32.72 and the average of 49.15. Its P/B of 7.04 is also above the industry median of 3.05 and average of 4.37. ROE at 4.29% is below the industry median of 11.69% and average of 10.54, while ROCE at 6.79% is below the median of 13.24% and average of 13.09. In market-cap terms, Rs 35,441.98 crore is well above the industry median of Rs 704.59 crore and above the average of Rs 13,873.11 crore.
That mix points to a large pharmaceutical company priced at higher-than-benchmark multiples while reporting lower-than-benchmark returns. For Wockhardt Share Price Fall Streak, that backdrop matters because it places the current decline into a broader valuation-and-profitability context without adding any unverified catalyst.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,41,957.5 | 36.54 | 5.11 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,47,576 | 84.64 | 14.02 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,89,233.01 | 86.76 | 21.08 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,11,670.55 | 24.74 | 4.14 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,10,272.68 | 32.72 | 3.14 | 11.83 | 16 |
Peer comparison reinforces the gap. Wockhardt’s market capitalisation of Rs 35,441.98 crore is smaller than Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla. Its P/E is close to Torrent and Divi’s, but its ROE and ROCE are lower than all five supplied peers, which keeps the stock’s relative setup under review.
For readers following Wockhardt Share Price Fall Streak, this is the most relevant comparison point: the stock is not only declining for a second straight session, it is doing so while carrying valuation and profitability metrics that sit out of line with much of the supplied peer group.
Why Investors Are Watching Wockhardt
Wockhardt Share Price Fall Streak is being watched because the decline is now cumulative, not isolated. The stock has closed lower for the second straight session, the streak has already reached 6.53%, and the latest close remained near the session low. Those facts make the move more notable than a routine daily fluctuation.
- The stock has now closed lower for the second straight session, taking the cumulative streak move to -6.53%.
- Today’s decline was 4.87%, with the close near the intraday low of Rs 2,068.4.
- Valuation remains elevated, with a P/E of 86.66 and a P/B of 7.04.
- Profitability metrics are modest, with ROE at 4.29% and ROCE at 6.79%.
- Sector and peer data show the company trades above industry median valuation despite lower return ratios.
About Wockhardt
Wockhardt is part of the Healthcare sector and is classified under the Pharmaceuticals & Drugs industry. In market-cap terms, it remains a sizable listed company at Rs 35,441.98 crore, and that makes Wockhardt Share Price Fall Streak relevant both as a stock-specific move and as a comparison point within the broader pharma universe.
Track Wockhardt on Univest
Readers tracking Wockhardt Share Price Fall Streak can use Univest to follow live price moves, market capitalisation, valuation ratios, peer comparison and sector benchmarks in one place. For investors monitoring Wockhardt Share Price Today and Wockhardt Latest News, Univest helps connect daily decline behaviour with broader fundamental context without relying on speculation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Wockhardt Share Price falling today?
Ans. The supplied data confirms that Wockhardt closed lower for the second straight session and fell 4.87% today to Rs 2,075. However, the verified figures do not establish any company-specific reason for the continued decline.
What is the latest Wockhardt Share Price today?
Ans. Wockhardt closed at Rs 2,075 on 15 September 2026. The stock declined Rs 106.15 from the previous close of Rs 2,181.15, making today’s move a 4.87% fall in the latest market session.
How much has Wockhardt fallen in the current streak?
Ans. Across the current two-session streak, Wockhardt has declined 6.53%. The streak base price was Rs 2,219.9 on 2026-09-11, and the latest closing price is Rs 2,075 after the second straight lower close.
What were Wockhardt's intraday levels in the latest session?
Ans. In the latest session, Wockhardt opened at Rs 2,184.75, touched a high of Rs 2,193.35 and a low of Rs 2,068.4, before ending at Rs 2,075. The close came only slightly above the day’s low.
What does the second straight session of decline indicate?
Ans. A second straight lower close shows a developing short-term price pattern rather than an isolated one-day fall. In Wockhardt’s case, the two-session decline totals 6.53%, which is why the stock is drawing fresh market attention.
What is Wockhardt 's market capitalisation?
Ans. Wockhardt’s market capitalisation stands at Rs 35,441.98 crore based on the supplied data. That places it well above the Pharmaceuticals & Drugs industry median market cap of Rs 704.59 crore within the 204-company benchmark set.
Is Wockhardt expensive compared with its industry benchmark?
Ans. On the supplied figures, Wockhardt trades at a P/E of 86.66 versus the industry median of 32.72 and average of 49.15. Its P/B of 7.04 is also above the industry median of 3.05.
How profitable is Wockhardt based on ROE and ROCE?
Ans. Wockhardt reports ROE of 4.29% and ROCE of 6.79% in the supplied data. Both are below the industry medians of 11.69% and 13.24%, indicating weaker return metrics than the broader benchmark.
How does Wockhardt compare with major pharma peers?
Ans. Wockhardt’s P/E of 86.66 is close to Torrent Pharmaceuticals at 86.76 and Divi's at 84.64, but its ROE of 4.29% and ROCE of 6.79% are below all five supplied peers in the comparison set.
What should investors monitor next in Wockhardt?
Ans. Investors may watch whether the two-session decline extends, how the stock behaves around recent levels near Rs 2,068.4 and Rs 2,075, and whether valuation and profitability metrics continue to keep the stock in focus on Univest.
Track Wockhardt (WOCKPHARMA) Share Price on Univest
UseWockhardt (WOCKPHARMA) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
